Fundz

Exsilio Therapeutics

NEW YORK, New York, United States · Healthcare, Health Care

Exsilio Therapeutics is developing genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions. Exsilio’s technology is based on naturally occurring genetic elements that can precisely insert new genes into a cell through RNA intermediate templates. Exsilio uses predictive in sil

Key facts

Headquarters
NEW YORK, New York, United States
Employees
41
Industries
Healthcare, Health Care
Status
Private
Website
avernatx.com
LinkedIn
Company page

Recent activity at Exsilio Therapeutics

Exsilio Therapeutics funding history

DateRoundAmount
Jun 2024Series A$82.0M

Leadership

  • Jake Olin, Vice President
  • Tom Barnes, Chief Executive Officer
  • Henry Chen, Board Member
  • Tal Zaks, Chairman
  • Tal Zaks, M.D., Ph.D., Director
  • Alex Harding, Director
  • Anat Nursella, Executive Officer
  • Stephen Squinto, Director
  • Roy Amariglio, Executive Officer

Verified email and direct lines for Exsilio Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Exsilio Therapeutics in the news

Companies similar to Exsilio Therapeutics

About Exsilio Therapeutics: questions and answers

What does Exsilio Therapeutics do?

Exsilio Therapeutics is developing genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions. Exsilio’s technology is based on naturally occurring genetic elements that can precisely insert new genes into a cell through RNA intermediate templates. Exsilio uses predictive in sil

Where is Exsilio Therapeutics headquartered?

Exsilio Therapeutics is headquartered in NEW YORK, New York, United States.

How many employees does Exsilio Therapeutics have?

Exsilio Therapeutics has about 41 employees.

Has Exsilio Therapeutics raised funding?

Yes. Fundz has recorded 1 funding event for Exsilio Therapeutics. The most recent, Series A of $82.0M, was in Jun 2024.

Who leads Exsilio Therapeutics?

Jake Olin is a Vice President at Exsilio Therapeutics.

What is the latest news on Exsilio Therapeutics?

On Mar 20, 2026, Exsilio Therapeutics

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Exsilio Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.